Inspire Medical Systems (NYSE:INSP) Price Target Lowered to $175.00 at Stifel Nicolaus

Inspire Medical Systems (NYSE:INSP) had its target price decreased by Stifel Nicolaus from $190.00 to $175.00 in a research note released on Monday morning,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Other research analysts also recently issued research reports about the company. Royal Bank of Canada dropped their price target on Inspire Medical Systems from $260.00 to $215.00 and set an “outperform” rating for the company in a research note on Tuesday, April 15th. Piper Sandler cut their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. KeyCorp decreased their price objective on Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating for the company in a report on Monday. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a report on Tuesday, February 11th. Finally, Truist Financial cut their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $218.90.

Inspire Medical Systems Stock Down 3.6 %

Shares of NYSE INSP opened at $144.74 on Monday. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40. The business’s 50 day moving average price is $165.31 and its two-hundred day moving average price is $182.56. The company has a market cap of $4.31 billion, a PE ratio of 83.67, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, research analysts anticipate that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. The trade was a 5.30 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds have recently bought and sold shares of the company. Mutual of America Capital Management LLC lifted its holdings in shares of Inspire Medical Systems by 1.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock valued at $842,000 after purchasing an additional 55 shares in the last quarter. True Wealth Design LLC boosted its holdings in shares of Inspire Medical Systems by 39.0% in the fourth quarter. True Wealth Design LLC now owns 196 shares of the company’s stock worth $36,000 after buying an additional 55 shares during the last quarter. Captrust Financial Advisors grew its position in Inspire Medical Systems by 2.0% during the fourth quarter. Captrust Financial Advisors now owns 3,034 shares of the company’s stock valued at $562,000 after buying an additional 59 shares during the period. MML Investors Services LLC increased its holdings in Inspire Medical Systems by 0.9% during the fourth quarter. MML Investors Services LLC now owns 7,941 shares of the company’s stock valued at $1,472,000 after buying an additional 67 shares during the last quarter. Finally, Mariner LLC boosted its stake in shares of Inspire Medical Systems by 1.6% during the 4th quarter. Mariner LLC now owns 4,837 shares of the company’s stock worth $897,000 after acquiring an additional 77 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.